

Hie-Won Hann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2577480/publications.pdf>

Version: 2024-02-01

31
papers

709
citations

623574

14
h-index

552653

26
g-index

32
all docs

32
docs citations

32
times ranked

1083
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive Analysis of Common Serum Liver Enzymes as Prospective Predictors of Hepatocellular Carcinoma in HBV Patients. PLoS ONE, 2012, 7, e47687.	1.1	67
2	Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection. Scientific Reports, 2016, 6, 23992.	1.6	66
3	Depression in Korean Immigrants With Hepatitis B and Related Liver Diseases. Psychosomatics, 2000, 41, 472-480.	2.5	56
4	Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. Clinical Gastroenterology and Hepatology, 2020, 18, 457-467.e21.	2.4	56
5	Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. Journal of Hepatology, 2017, 66, 11-18.	1.8	52
6	Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma. Hepatoma Research, 2017, 3, 105.	0.6	47
7	Then and now: The progress in hepatitis B treatment over the past 20 years. World Journal of Gastroenterology, 2014, 20, 401.	1.4	47
8	Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). Hepatology International, 2008, 2, 244-249.	1.9	39
9	A long-term study of the effects of antiviral therapy on survival of patients with HBV-associated hepatocellular carcinoma (HCC) following local tumor ablation. Cancer Medicine, 2014, 3, 390-396.	1.3	35
10	Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure. Diseases (Basel, Switzerland), 2018, 6, 27.	1.0	25
11	Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection. Journal of Hepatology, 2022, 77, 1265-1275.	1.8	21
12	Prevention of new hepatocellular carcinoma with concomitant antiviral therapy in chronic hepatitis B patients whose initial tumor was successfully ablated. International Journal of Cancer, 2011, 128, 739-742.	2.3	18
13	Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection. Journal of Hepatology, 2022, 77, 642-652.	1.8	17
14	Analysis of GP73 in patients with HCC as a function of anti-cancer treatment. Cancer Biomarkers, 2011, 7, 269-273.	0.8	16
15	Alpha-Fetoprotein (AFP) and AFP-L3 Is Most Useful in Detection of Recurrence of Hepatocellular Carcinoma in Patients after Tumor Ablation and with Low AFP Level. Viruses, 2022, 14, 775.	1.5	16
16	Ferritin level prospectively predicts hepatocarcinogenesis in patients with chronic hepatitis B virus infection. Oncology Letters, 2018, 16, 3499-3508.	0.8	15
17	Urine DNA biomarkers for hepatocellular carcinoma screening. British Journal of Cancer, 2022, 126, 1432-1438.	2.9	15
18	A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B. Hepatology International, 2008, 2, 440-456.	1.9	14

#	ARTICLE	IF	CITATIONS
19	HBV-related health behaviors in a socio-cultural context: Perspectives from Khmers and Koreans. Applied Nursing Research, 2014, 27, 127-132.	1.0	14
20	Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. World Journal of Hepatology, 2019, 11, 65-73.	0.8	12
21	Detection of Hepatitis B Virus“Host Junction Sequences in Urine of Infected Patients. Hepatology Communications, 2021, 5, 1649-1659.	2.0	11
22	Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses. Expert Opinion on Pharmacotherapy, 2010, 11, 2243-2249.	0.9	9
23	Gender Disparity in Host Responses to Hepatitis B-Related Hepatocellular Carcinoma: A Case Series. Vaccines, 2021, 9, 838.	2.1	8
24	First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alafenamide. Hepatology Communications, 2022, 6, 1881-1894.	2.0	7
25	Prospective and longitudinal evaluations of telomere length of circulating DNA as a risk predictor of hepatocellular carcinoma in HBV patients. Carcinogenesis, 2017, 38, 439-446.	1.3	6
26	Vagaries of the Host Response in the Development of Hepatitis B-related Hepatocellular Carcinoma: A Case Series. Current Cancer Therapy Reviews, 2020, 16, 253-258.	0.2	5
27	Hepatitis B Virus-Associated Hepatocellular Carcinoma and Chronic Stress. International Journal of Molecular Sciences, 2022, 23, 3917.	1.8	5
28	Hepatitis B-related hepatocellular carcinoma and stress: untangling the host immune response from clinical outcomes. Hepatic Oncology, 2021, 8, HEP35.	4.2	4
29	“The host’s role in hepatocellular carcinoma development: A case of regression from probable malignancy to a benign lesion”. Integrative Cancer Science and Therapeutics, 2019, 6, .	0.1	3
30	Vagaries of the Host Response to Chronic Hepatitis B Virus Infection: What is the Ultimate Outcome of So-called “Asymptomatic HBV Carriers” Observed Over Several Decades?. Journal of Immunological Sciences, 2021, 5, 15-20.	0.5	3
31	IDDF2020-ABS-0058“...48-week safety and efficacy of switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) in chronic HBV asian patients with TDF risk factors (RF). , 2020, , .		0